Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
JCI Insight|January 25, 2019
Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneityLing Li, Hildur Knutsdottir, Ken Hui, et al.Journal of Cellular and Molecular Medicine|December 9, 2024
The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid LeukaemiaSonia Zicari, Giuseppe Merlino, Alessandro Paoli, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemiaKyle Zacholski, Bryan Hambley, Erin Hickey, et al.The Journal of Infectious Diseases|January 26, 2012
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapyChristine M Durand, Gabriel Ghiaur, Janet D Siliciano, et al.Science Advances|February 18, 2022
The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemiaTheodoros Karantanos, Patric Teodorescu, Brandy Perkins, et al.Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.Journal of Cellular Physiology|March 16, 2017
Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosisCiprian Tomuleasa, Sonia Selicean, Grigore Gafencu, et al.Pageof 10